Trial record 2 of 4 for:    EDP-938

A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03691623
Recruitment Status : Recruiting
First Posted : October 2, 2018
Last Update Posted : October 17, 2018
hVIVO Services Limited
Information provided by (Responsible Party):
Enanta Pharmaceuticals

Brief Summary:
A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to compare the antiviral effect of EDP-938 compared to a placebo control in the respiratory syncytial virus challenge model.

Condition or disease Intervention/treatment Phase
RSV Infection Drug: EDP-938 Dose 1 Drug: EDP-938 Dose 2 Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 114 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model.
Estimated Study Start Date : October 2018
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: EDP-938 Arm A
Subjects will take EDP-938 Dose 1 oral suspension for 5 days
Drug: EDP-938 Dose 1
Oral suspension for 5 days

Experimental: EDP-938 Arm B
Subjects will take EDP-938 Dose 2 oral suspension for 5 days
Drug: EDP-938 Dose 2
Oral suspension for 5 days

Placebo Comparator: Placebo
Subjects will take matching placebo oral suspension for 5 days
Drug: Placebo
Oral suspension for 5 days

Primary Outcome Measures :
  1. Change in viral load measurements [ Time Frame: Post initial dose of EDP-938 up to Day 12 ]
    Area under the curve for RSV viral load as measured by RT-qPCR assay from the first viral load measurement post initial dose of EDP-938 or placebo through day 12

Secondary Outcome Measures :
  1. Change of baseline symptoms [ Time Frame: Innoculation through Day 12 ]
    Change of baseline symptoms post initial dose of EDP-938 or placebo through Day 12

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • An informed consent document signed and dated by the subject.
  • Age 18 to 55 years, inclusive.
  • In good health with no history of major medical conditions
  • A total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 30kg/m2

Exclusion Criteria:

  • Pregnant or nursing females
  • Acute or chronic medical illness
  • Abnormal lung function
  • Positive for HIV, active hepatitis A, B or C test
  • Nose or nasopharynx abnormalities
  • Receipt of any investigational drug within 3 months prior to the planned date of viral challenge/first dose of study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03691623

Contact: Enanta Pharmaceuticals, Inc 617 607 0705

United Kingdom
hVIVO Services Limited (hVIVO) Recruiting
London, United Kingdom
Principal Investigator: Mehrnaz Tadayon, MD         
Sponsors and Collaborators
Enanta Pharmaceuticals
hVIVO Services Limited
Study Director: Enanta Pharmaceuticals, Inc Enanta Pharmaceuticals, Inc

Responsible Party: Enanta Pharmaceuticals Identifier: NCT03691623     History of Changes
Other Study ID Numbers: EDP 938-101
First Posted: October 2, 2018    Key Record Dates
Last Update Posted: October 17, 2018
Last Verified: September 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Enanta Pharmaceuticals:
challenge study
RSV-A Memphis 37b

Additional relevant MeSH terms:
Respiratory Syncytial Virus Infections
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases